Abstract
Objectives: Decreased pepsinogen level is characteristic for atrophy of the
stomach mucosa, and is suggested to be used for gastric cancer risk screening.
Several test-systems are available to measure pepsinogens. The objective
of the current study was to evaluate the proportion of gastric cancer patients
presenting decreased pepsinogen levels when measured by three different
assays.
Methods: 184 gastric cancer patients (males 110/184, median age 65
years) with gastric cancer were enrolled. All cases were classified according to
Lauren classification: intestinal (57 cases), diffuse (43 cases), mixed (48 cases)
and indeterminate (10 cases). Blood samples were obtained prior surgery. For
each patient level of pepsinogen I (PgI) and pepsinogen II (PgII) was determined
with three different test-systems: two ELISA tests - Biohit (Finland) and Vector
Best (Russia) as well as one latex agglutination test - Eiken (Japan). PgI and
PgII ratio (PgI/II) < 3 was considered positive for atrophy.
Results: Pepsinogen
test was positive in 34.2% of all patients with Biohit, 42.4% with Vector Best,
and 69.6% with Eiken test-system; for intestinal-type cancers the positivity rate
was 50.9%, 56.1%, and 82.5%, but for diffuse-type cancers – 20.9%, 27.9%, and
58.1%, respectively.
Conclusions: The performance of different pepsinogen
tests to identify increased gastric cancer risk may be different. However, before
these findings could be translated to clinical recommendations, the comparative
accuracy of each test-system to detect atrophy should be evaluated.
stomach mucosa, and is suggested to be used for gastric cancer risk screening.
Several test-systems are available to measure pepsinogens. The objective
of the current study was to evaluate the proportion of gastric cancer patients
presenting decreased pepsinogen levels when measured by three different
assays.
Methods: 184 gastric cancer patients (males 110/184, median age 65
years) with gastric cancer were enrolled. All cases were classified according to
Lauren classification: intestinal (57 cases), diffuse (43 cases), mixed (48 cases)
and indeterminate (10 cases). Blood samples were obtained prior surgery. For
each patient level of pepsinogen I (PgI) and pepsinogen II (PgII) was determined
with three different test-systems: two ELISA tests - Biohit (Finland) and Vector
Best (Russia) as well as one latex agglutination test - Eiken (Japan). PgI and
PgII ratio (PgI/II) < 3 was considered positive for atrophy.
Results: Pepsinogen
test was positive in 34.2% of all patients with Biohit, 42.4% with Vector Best,
and 69.6% with Eiken test-system; for intestinal-type cancers the positivity rate
was 50.9%, 56.1%, and 82.5%, but for diffuse-type cancers – 20.9%, 27.9%, and
58.1%, respectively.
Conclusions: The performance of different pepsinogen
tests to identify increased gastric cancer risk may be different. However, before
these findings could be translated to clinical recommendations, the comparative
accuracy of each test-system to detect atrophy should be evaluated.
| Original language | English |
|---|---|
| Pages | 53 |
| Number of pages | 1 |
| Publication status | Published - Jun 2013 |
| Externally published | Yes |
| Event | 10th International Gastric Cancer Congress (IGCC) - Verona, Italy Duration: 19 Jun 2013 → 22 Jun 2013 Conference number: 10 https://www.igca.info/news/apl2013_01.html |
Congress
| Congress | 10th International Gastric Cancer Congress (IGCC) |
|---|---|
| Abbreviated title | IGCC 2013 |
| Country/Territory | Italy |
| City | Verona |
| Period | 19/06/13 → 22/06/13 |
| Internet address |
Field of Science*
- 3.2 Clinical medicine
- 3.1 Basic medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)
